You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RRMM

Showing 1 - 25 of 174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

RRMM, Other Plasma Cell Diseases Trial (LM-305, Dexamethasone)

Not yet recruiting
  • RRMM
  • Other Plasma Cell Diseases
  • (no location specified)
Dec 1, 2022

Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Amyloid Light-chain Amyloidosis
  • (no location specified)
Apr 20, 2023

Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma (RRMM)
  • Non-Interventional
  • (no location specified)
Dec 21, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Jun 8, 2023

Quality of Life in Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
  • Multiple Myeloma
    • Morrisville, North Carolina
      Local Institution
    May 12, 2022

    Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Philadelphia, Pennsylvania
      Hospital of the University of Pennsylvania
    Apr 7, 2023

    Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial run by the

    Not yet recruiting
    • Multiple Myeloma
    • +2 more
    • 18F-fluciclovine injection
    • 18F-FDG PET/CT
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Oct 31, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

    Withdrawn
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Jan 26, 2023

    Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)

    Not yet recruiting
    • Multiple Myeloma
    • Primary Plasma Cell Leukemia
    • Experimental: CAR-T cells Infusion
    • Shanghai, China
      Shanghai Changzheng Hospital
    Apr 20, 2023

    RRMM Trial in Worldwide (Melphalan-flufenamide, Dexamethasone)

    Terminated
    Has Results
    • RRMM
    • Glendale, California
    • +9 more
    Jul 18, 2022

    Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • (no location specified)
    Feb 3, 2023

    Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma
    • +4 more
    • Chapel Hill, North Carolina
    • +2 more
    Jun 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • BCMA CAR-NK
    • +2 more
    • Hangzhou, Zhejiang, China
    • +1 more
    Feb 17, 2023

    Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission Trial in United States (FOR46)

    Completed
    • Multiple Myeloma
    • +2 more
    • San Francisco, California
    • +6 more
    Jul 25, 2022

    Relapsed/Refractory Multiple Myeloma Trial (AMG 701)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • AMG 701
    • (no location specified)
    Jun 6, 2022

    Multiple Myeloma Trial (Pembrolizumab, Pomalidomide, Dexamethasone)

    Terminated
    Has Results
    • Multiple Myeloma
    • Pembrolizumab
    • +2 more
    • (no location specified)
    Sep 13, 2021

    Relapsed/Refractory Multiple Myeloma With Pomalidomide in

    Recruiting
    • Multiple Myeloma
    • Feldkirch, Austria
    • +12 more
    May 16, 2022

    Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)

    Recruiting
    • Multiple Myeloma
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Mar 3, 2022

    Multiple Myeloma Trial in Zhengzhou, Wuhan, Xi'an (Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin)

    Recruiting
    • Multiple Myeloma
    • Selinexor (80mg/d)
    • +4 more
    • Zhengzhou, Henan, China
    • +4 more
    Aug 16, 2022

    Relapsed or Refractory Multiple Myeloma Trial in Canada, United States (mRNA-2736)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • mRNA-2736
    • Birmingham, Alabama
    • +12 more
    Jun 15, 2023

    Plasma Cell Myeloma Refractory Trial in Worldwide (Isatuximab SAR650984, Dexamethasone, Pomalidomide)

    Recruiting
    • Plasma Cell Myeloma Refractory
    • Isatuximab SAR650984
    • +4 more
    • Chicago, Illinois
    • +18 more
    Aug 2, 2022

    Multiple Myeloma Trial in United States (Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone)

    Recruiting
    • Multiple Myeloma
    • Ruxolitinib Oral Tablet [Jakafi]
    • +2 more
    • Alhambra, California
    • +12 more
    Apr 18, 2022

    Renal Impairment, RRMM Trial in Czechia, Greece, Poland (Melphalan flufenamide (melflufen), Dexamethasone)

    Terminated
    • Renal Impairment
    • RRMM
    • Brno, Czechia
    • +9 more
    Feb 2, 2022

    Multiple Myeloma Trial in Worldwide (isatuximab SAR650984 IV, pomalidomide, dexamethasone)

    Active, not recruiting
    • Multiple Myeloma
    • isatuximab SAR650984 IV
    • +4 more
    • Gilbert, Arizona
    • +14 more
    May 6, 2022

    Plasma Cell Myeloma Trial in United States (isatuximab SAR650984, lenalidomide, dexamethasone)

    Active, not recruiting
    • Plasma Cell Myeloma
    • isatuximab SAR650984
    • +2 more
    • San Francisco, California
    • +4 more
    Jun 16, 2022